Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

• Status: Recruiting
• Trial end date: 2022-05-13

Summary

The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

• Phase: Phase 2

Details

• Lead Sponsor: Cardiff Oncology; Trovagene, Inc.
• Treatments: Onvansertib; Prednisone